Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54
Mandate

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54

November 11, 2021 M&A Intellectual Property Commercial Agreements Employment and Benefits

Vinge advised FACT-Finder on its acquisition of real-time AI-personalization vendor Loop54 making it one of the first major consolidations of leading e-commerce SaaS solutions in search, merch and personalization.

The merging of their proprietary algorithms will enable FACT-Finder customers to provide digital experiences that are unlike any other on the market and further expand FACT-Finder's international presence.

Vinge’s team consisted of responsible partner Matthias Pannier and associates Vilhelm Rondahl, Gustav Persson, Ebba Nyberg (M&A), Isabell Nielsen, Karl-Gustaw Tobola, Karolina Fuhrmann (Commercial Agreements/IT), Sofia Bergenstråhle (Intellectual Property), Carl Östlund (Employment), Karl-Hugo Engdahl (GDPR) and Ulf Pyk (Real Estate).

 

Related

Vinge advises Vinci Concessions SAS and its subsidiary SunMind SAS in connection with its acquisition of Helios Nordic Energy AB from Magnora ASA, management and early investors

 Helios Nordic Energy specialises in developing solar farms and batteries to store energy until they become Ready to Build in the Nordics and Baltics.
May 30, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
May 28, 2024

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

 On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.
May 28, 2024